Quote | Codex DNA Inc. (NASDAQ:DNAY)
Last: | $1.30 |
---|---|
Change Percent: | 0.0% |
Open: | $1.2 |
Close: | $1.30 |
High: | $1.3093 |
Low: | $1.2 |
Volume: | 19,956 |
Last Trade Date Time: | 01/03/2023 03:40:04 pm |
News | Codex DNA Inc. (NASDAQ:DNAY)
Telesis Bio press release ( NASDAQ: DNAY ): Q3 GAAP EPS of -$0.42 beats by $0.05 . Revenue of $6.68M (+138.6% Y/Y) beats by $1.38M . 2022 Financial Guidance Revenue is now expected to be between $23 million and $25 million, an increase from previous guidanc...
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...
Message Board Posts | Codex DNA Inc. (NASDAQ:DNAY)
Subject | By | Source | When |
---|---|---|---|
Headed to zero apparently. Anyone know if there's | observer21 | investorshub | 07/15/2022 5:57:33 PM |
Low float with a heavy short on 52week | HoldEm777 | investorshub | 03/24/2022 3:45:26 PM |
I think now it begins | scotsand | investorshub | 03/24/2022 3:17:33 PM |
I personally think this is a full reversal | HoldEm777 | investorshub | 03/11/2022 8:14:49 PM |
I wondered when anyone would ever show up | observer21 | investorshub | 01/17/2022 4:09:49 AM |
News, Short Squeeze, Breakout and More Instantly...
Codex DNA Inc. Company Name:
DNAY Stock Symbol:
NASDAQ Market:
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction ...
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and valid...